Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD1 | P21728 | 14/20 | 0.54 |
| ▸ | DRD3 | P35462 | 10/20 | 0.54 |
| ▸ | DRD2 | P14416 | 10/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.54 |
| ▸ | F3 | P13726 | 4/20 | 0.52 |
| ▸ | DRD5 | P21918 | 3/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | DRD4 | P21917 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29999642 | 1.00 | DRD1 (0.54) | DRD1DRD3DRD2SIGMAR1F3 | |
| SCHEMBL2742603 | 0.93 | DRD1 (0.55) | DRD1DRD3DRD2SIGMAR1F3 | |
| SCHEMBL30000441 | 0.92 | DRD1 (0.62) | DRD1DRD3DRD2SIGMAR1F3 | |
| SCHEMBL909815 | 0.92 | DRD1 (0.62) | DRD1DRD3DRD2SIGMAR1F3 | |
| SCHEMBL910650 | 0.92 | DRD1 (0.51) | DRD1DRD3DRD2SIGMAR1F3 | |
| SCHEMBL29999646 | 0.92 | DRD1 (0.51) | DRD1DRD3DRD2SIGMAR1F3 | |
| SCHEMBL29999727 | 0.91 | DRD1 (0.51) | DRD1DRD3DRD2SIGMAR1F3 | |
| SCHEMBL910411 | 0.91 | DRD1 (0.51) | DRD1DRD3DRD2SIGMAR1F3 | |
| SCHEMBL910018 | 0.90 | DRD1 (0.62) | DRD1DRD3DRD2SIGMAR1F3 | |
| SCHEMBL30000502 | 0.90 | DRD1 (0.62) | DRD1DRD3DRD2SIGMAR1F3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220387403-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING NASH, NAFLD, AND OBESITY | CVI PHARMACEUTICALS LIMITED (KY) | 2022-12-08 | — | — | US | disclosed |
| US-20220387403-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING NASH, NAFLD, AND OBESITY | CVI PHARMACEUTICALS LIMITED (KY) | 2022-12-08 | — | — | US | disclosed |
| EP-2370434-B1 | ISOQUINOLINYL-CONTAINING ALKALOID COMPOUNDS AND COMPOSITIONS USEFUL FOR REDUCING LIPID LEVELS | CVI PHARMACEUTICALS LTD (KY) | 2014-09-17 | — | — | EP | disclosed |
| US-8710071-B2 | Compounds, compositions and methods for reducing lipid levels | CVI PHARMACEUTICALS LIMITED (KY) | 2014-04-29 | — | — | US | disclosed |
| US-8710071-B2 | Compounds, compositions and methods for reducing lipid levels | CVI PHARMACEUTICALS LIMITED (KY) | 2014-04-29 | — | — | US | disclosed |
| US-20120004223-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR REDUCING LIPID LEVELS | CVI PHARMACEUTICALS LIMITED (KY) | 2012-01-05 | — | — | US | disclosed |
| US-20120004223-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR REDUCING LIPID LEVELS | CVI PHARMACEUTICALS LIMITED (KY) | 2012-01-05 | — | — | US | disclosed |
| US-20110009628-A1 | Compounds and Compositions for Modulating Lipid Levels and Methods of Preparing Same | CVI PHARMACEUTICALS LIMITED (KY) | 2011-01-13 | — | — | US | disclosed |
| US-20110009628-A1 | Compounds and Compositions for Modulating Lipid Levels and Methods of Preparing Same | CVI PHARMACEUTICALS LIMITED (KY) | 2011-01-13 | — | — | US | disclosed |
| US-20110009628-A1 | Compounds and Compositions for Modulating Lipid Levels and Methods of Preparing Same | CVI PHARMACEUTICALS LIMITED (KY) | 2011-01-13 | — | — | US | disclosed |
| WO-2011006000-A1 | BERBERINE DERIVATIVES USEFUL FOR MODULATING LIPID LEVELS AND THEIR METHODS OF SYNTHESIS | LIU HAIYAN (US) | 2011-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009628-A1 | Compounds and Compositions for Modulating Lipid Levels and Methods of Preparing Same | LIPC, LDLR, PCSK9 | DRD1 4873/4885DRD3 4832/4885DRD2 4863/4885 |
| US-20220387403-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING NASH, NAFLD, AND OBESITY | LIPC, FABP1, CPT1A | DRD1 4727/4885DRD3 4182/4885DRD2 4557/4885 |
| US-20120004223-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR REDUCING LIPID LEVELS | LIPC, LDLR, PCSK9 | DRD1 4858/4885DRD3 4783/4885DRD2 4824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.